Biopharmaceutical company improves real-time visibility into quality
documents
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that Samsung
BioLogics selected Veeva
Vault QualityDocs to modernize quality document management. Vault
QualityDocs enables Samsung BioLogics to provide transparency into
content status and processes for internal and external users, partners,
and suppliers worldwide. The company can also better scale its document
control processes and ensure global alignment across the business.
Samsung BioLogics, based in South Korea, aimed to improve operational
efficiency by giving global stakeholders easy and secure access to
quality documents. External users can access Vault QualityDocs from
anywhere, anytime in the cloud for greater agility. As a result, Vault
QualityDocs will provide Samsung BioLogics with a single source of truth
for quality documents.
“Vault QualityDocs will help support Samsung BioLogics’ strategic
vision,” said Chie Soo Rhee, senior IT specialist of quality IT systems
at Samsung BioLogics. “We look forward to partnering with Veeva to bring
together our global quality processes.”
“With Vault QualityDocs, life sciences companies and contract
manufacturing organizations can collaborate securely and gain greater
transparency into global quality procedures,” said Chris Shim, country
manager for Veeva Korea. “Samsung BioLogics is committed to the highest
quality standards, and we’re honored to be chosen as a strategic
technology partner.”
Vault QualityDocs is a modern, cloud-based application for GxP document
control and management that delivers greater compliance, improved
quality, and reduced operational overhead. It is part of Veeva
Vault Quality Suite that unifies quality processes, document
control, and training to drive global operational innovation.
Additional Information
For more on Veeva Vault QualityDocs, visit: veeva.com/QualityDocs
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Samsung BioLogics
Samsung BioLogics is a world-class contract manufacturing organization
(CMO) committed to quality-driven manufacturing of biopharmaceutical
products. Its customer-oriented business model supports both
collaborative novel drug development and high-quality, fast-turnaround
contract manufacturing partnerships. Samsung BioLogics aims to
strengthen its presence in the rapidly growing global biopharmaceutical
market by utilizing its world-class plant design and operation
technology that maximizes production efficiency and ensure the highest
quality products for the patient. For more information, please visit: www.samsungbiologics.com.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 625 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180718005253/en/
Veeva Systems
Roger Villareal, 925-264-8885
roger.villareal@veeva.com
or
Lisa
Barbadora, 610-420-3413
pr@veeva.com
Source: Veeva Systems Inc.